Under the agreements, MSD will provide licences to these manufacturers to supply molnupiravir to India and more than 100 LMICs. MSD is also in discussions with the Medicines Patent Pool to explore the potential for additional licences.MSD enters licensing pact with five Indian generic firms to manufacture, distribute COVID-19 antiviral drug molnupiravir
Under the agreements, MSD will provide licences to these manufacturers to supply molnupiravir to India and more than 100 LMICs. MSD is also in discussions with the Medicines Patent Pool to explore the potential for additional licences.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The bank plans to raise up to Rs 500 crore by issue of equity shares to qualified institutional buyers through qualified institutional plac...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment